2. Search Result
Search Result
Results for "

Aβ25-35

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

4

Peptides

15

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0128
    β-Amyloid (25-35)
    Maximum Cited Publications
    30 Publications Verification

    Amyloid beta-peptide (25-35); Aβ25-35; β-Amyloid peptide (25-35)

    		 Amyloid-β Neurological Disease
    β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .
    β-Amyloid (25-35)
  • HY-117049
    Leucettine L41
    1 Publications Verification

    		 CDK DYRK Neurological Disease
    Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 µM, respectively) . Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ25-35 in the same model .
    Leucettine L41
  • HY-N0702
    Tenuifolin

    		Beta-secretase Cholinesterase (ChE) Neurological Disease
    Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD).
    Tenuifolin
  • HY-116753
    (-)Clausenamide

    		Amyloid-β Tau Protein Neurological Disease
    (-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .
    (-)Clausenamide
  • HY-P0128A
    β-Amyloid (25-35), HFIP-treated

    Amyloid beta-peptide (25-35), HFIP-treated; Aβ25-35, HFIP-treated; β-Amyloid peptide (25-35), HFIP-treated

    		 Amyloid-β Neurological Disease
    β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .
    β-Amyloid (25-35), HFIP-treated
  • HY-P5968
    [Ala28]-β Amyloid(25-35)

    β(25-35)KA

    		 Amyloid-β Neurological Disease
    [Ala28]-β Amyloid(25-35) (β(25-35)KA) is an electrically neutral mutant peptide of Aβ(25-35) that accelerates the aggregation of Firefly Luciferase .
    [Ala28]-β Amyloid(25-35)
  • HY-N8103
    Heishuixiecaoline A

    		Amyloid-β Neurological Disease
    Heishuixiecaoline A is a germacrane-type sesquiterpenoid. Heishuixiecaoline A shows protective effect on the neurotoxicity of PC12 cells induced by Aβ25-35 .
    Heishuixiecaoline A
  • HY-N9928
    Echinenone

    		Cholinesterase (ChE) Neurological Disease
    Echinenone is an acetylcholinesterase (AChE) inhibitor (IC50=16.29 μg/mL) with anti-Aβ(25-35) activity. Echinenone can inhibit MDA content and increase superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) activities to cope with oxidative stress damage .
    Echinenone
  • HY-157384
    BChE-IN-22

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-22 (compound 5A) is a selective eqBChE inhibitor (IC50: 0.53 μM), has anti-inflammatory and neuroprotective activities. BChE-IN-22 can inhibit cell damage caused by Aβ25-35 (HY-P0128) and improve cognitive dysfunction caused by Scopolamine (HY-N0296) .
    BChE-IN-22
  • HY-N0702R
    Tenuifolin (Standard)

    		Beta-secretase Cholinesterase (ChE) Neurological Disease
    Tenuifolin (Standard) is the analytical standard of Tenuifolin. This product is intended for research and analytical applications. Tenuifolin is effective and has a protective action. Tenuifolin inhibits β-secretase decreases Aβ protein secretion, suppresses Aβ25-35 secretion, and subsequently caspase-3 and caspase-9 become active. Tenuifolin's ability to lower AChE activity, increase at the same time, increase the ability of the upper glands, and improve the ability to read and remember. Research on tenuifolin's potential for use in urinary disease (AD) .
    Tenuifolin (Standard)
  • HY-N0028
    Forsythiaside A
    3 Publications Verification

    		 Others Inflammation/Immunology
    Forsythiaside A is an orally active phenylethanoid glycoside isolated from the dried fruits of Forsythia suspensa. Forsythiaside A is also an inhibitor of COX-2 and has anti-inflammatory, antioxidant and neuroprotective effects. Forsythiaside A prevents neuroinflammation and apoptosis caused by Aβ25-35 damage and may be used in Alzheimer's disease (AD) research. Forsythiaside A also activates the Nrf2/HO-1 signaling pathway and inhibits OVA-induced asthma in mice. Forsythiaside A inhibits the interaction between KLRB1 and CLEC2D .
    Forsythiaside A
  • HY-N0028R
    Forsythiaside A (Standard)

    		Others Inflammation/Immunology
    Forsythiaside A (Standard) is the analytical standard of Forsythiaside A. This product is intended for research and analytical applications. Forsythiaside A is an orally active phenylethanoid glycoside isolated from the dried fruits of Forsythia suspensa. Forsythiaside A is also an inhibitor of COX-2 and has anti-inflammatory, antioxidant and neuroprotective effects. Forsythiaside A prevents neuroinflammation and apoptosis caused by Aβ25-35 damage and may be used in Alzheimer's disease (AD) research. Forsythiaside A also activates the Nrf2/HO-1 signaling pathway and inhibits OVA-induced asthma in mice .
    Forsythiaside A (Standard)
  • HY-149845
    PROTAC GSK-3β Degrader-1

    		GSK-3 PROTACs Neurological Disease
    PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets GSK-3β degradation with an IC50 value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand). PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ25-35 peptide and CuSO4. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease .
    PROTAC GSK-3β Degrader-1
  • HY-P4832
    Acetyl-Tau Peptide (273-284) amide

    		Amyloid-β Neurological Disease
    Acetyl-Tau Peptide (273-284) amide is an acetylated Tau peptide fragment. Acetyl-Tau Peptide (273-284) amide limits the substantial aggregation of Ac-Aβ(25–35)-NH2 and can be used as an inhibitor of Ac-Aβ(25–35)-NH2. Acetyl-Tau Peptide (273-284) amide can be used as an experimental model to investigate the Aβ/Tau cross-interaction .
    Acetyl-Tau Peptide (273-284) amide
  • HY-N4098
    Incensole Acetate

    		Apoptosis Neurological Disease
    Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .
    Incensole Acetate
  • HY-N4098R
    Incensole Acetate (Standard)

    		Apoptosis Neurological Disease
    Incensole Acetate (Standard) is the analytical standard of Incensole Acetate. This product is intended for research and analytical applications. Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .
    Incensole Acetate (Standard)
  • HY-N3489
    Isodihydrofutoquinol B

    		Others Neurological Disease
    Isodihydrofutoquinol B (compound 9), an active compound, can be isolated from the stems of Piper kadsura (Choisy) Ohwi. Isodihydrofutoquinol B has A neuroprotective effect on Aβ25-35-induced PC12 cell damage with E50 values of 3.06-29.3μM .
    Isodihydrofutoquinol B
  • HY-157394
    eeAChE/eqBuChE-IN-1

    		Cholinesterase (ChE) Inflammation/Immunology
    eeAChE/eqBuChE-IN-1 (compound 3F) is a reversible dual eeAChE/eqBuChE inhibitor with IC50s of 1.3?μM and 0.81?μM, respectively. eeAChE/eqBuChE-IN-1 exhibits anti-inflammatory activity. eeAChE/eqBuChE-IN-1 also shows neuroprotective effect on Aβ25-35-induced PC12 cell injury .
    eeAChE/eqBuChE-IN-1
  • HY-N0894A
    (3R,5R)-Octahydrocurcumin

    (3R,5R)-Hexahydrobisdemethoxycurcumin

    		 Drug Metabolite Neurological Disease Inflammation/Immunology
    (3R,5R)-Octahydrocurcumin (Compound 7) is gut microbial metabolite of Curcumin (HY-N0005). (3R,5R)-Octahydrocurcumin exhibits neuroprotective efficacy against Aβ25-35-induced cell damage in SH-SY5Y, and anti-inflammatory activity against LPS-stimulated mouse microglial BV-2 .
    (3R,5R)-Octahydrocurcumin
  • HY-146619
    RAGE/SERT-IN-1

    		Amyloid-β Serotonin Transporter Neurological Disease
    RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC50s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression .
    RAGE/SERT-IN-1
  • HY-103539
    3,5-Bis(4-nitrophenoxy)benzoic acid

    		γ-secretase Metabolic Disease
    3,5-Bis(4-nitrophenoxy)benzoic acid is an inhibitor of γ-secretase. 3,5-Bis(4-nitrophenoxy)benzoic acid causes a decrease in the released levels of Aβ42 and notch-1 Aβ-like peptide 25 (Nβ25). 3,5-Bis(4-nitrophenoxy)benzoic acid, as a marker for fetal hypothyroidism, is a 3,3’-diiodothyronine sulfate (T2S) cross-reactive material in maternal serum .
    3,5-Bis(4-nitrophenoxy)benzoic acid
  • HY-106353
    Smilagenin
    1 Publications Verification

    		 mAChR Endogenous Metabolite Neurological Disease
    Smilagenin (SMI) is a small-molecule steroidal sapogenin from Anemarrhena asphodeloides and Pelargonium hortorum widely used in traditional Chinese medicine for treating chronic neurodegeneration diseases . Smilagenin (SMI) improves memory of aged rats by increasing the muscarinic receptor subtype 1 (M1)-receptor density . Smilagenin (SMI) attenuates Aβ(25-35)-induced neurodegenerationvia stimulating the gene expression of brain-derived neurotrophic factor, may represents a novel therapeutic strategy for AD .
    Smilagenin
  • HY-106353R
    Smilagenin (Standard)

    		mAChR Endogenous Metabolite Neurological Disease
    Smilagenin (Standard) is the analytical standard of Smilagenin. This product is intended for research and analytical applications. Smilagenin (SMI) is a small-molecule steroidal sapogenin from Anemarrhena asphodeloides and Pelargonium hortorum widely used in traditional Chinese medicine for treating chronic neurodegeneration diseases . Smilagenin (SMI) improves memory of aged rats by increasing the muscarinic receptor subtype 1 (M1)-receptor density . Smilagenin (SMI) attenuates Aβ(25-35)-induced neurodegenerationvia stimulating the gene expression of brain-derived neurotrophic factor, may represents a novel therapeutic strategy for AD .
    Smilagenin (Standard)
  • HY-D0186
    2'-Deoxyuridine
    1 Publications Verification

    		 Endogenous Metabolite Thymidylate Synthase Infection
    2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) .
    2'-Deoxyuridine
  • HY-D0186R
    2'-Deoxyuridine (Standard)

    		Endogenous Metabolite Thymidylate Synthase Infection
    2'-Deoxyuridine (Standard) is the analytical standard of 2'-Deoxyuridine. This product is intended for research and analytical applications. 2’-deoxyuridine is a brain-penetrant pyrimidines nucleotide that is associated with nervous system diseases. 2'-Deoxyuridine could increase chromosome breakage and results in a decreased thymidylate synthetase activity. 2'-Deoxyuridine is a precursor in the synthesis of Edoxudine (HY-B1011) and also an analogue of 5-ethynyl-2'-deoxyuridine, EdU (HY-118411). 2’-deoxyuridine reduces microglial activation and improve oxidative stress damage by modulating glycolytic metabolism on the Aβ25-35-induced brain injury, which is promising for research of Alzheimer’s disease (AD) . In Vitro:The interaction between the 2-deoxyuridine and the column increases the duration of retention of 2-deoxyuridine .
    Gradient elution with sodium acetate buffer-ACN eluent on two ZIC-HILIC homemade columns separates 2-deoxyuridine in under 9 min .
    In Vivo:2'-Deoxyuridine (34.42 ng/mL, gavage, 15 min) passes the blood-brain barrier (BBB) to enter the hippocampus of mice brain .
    2'-Deoxyuridine (20 mg/kg, gavage, daily for 4 weeks) improves cognition and memory loss and attenuates the damage to the hippocampus in Aβ25-35-induced mice model .
    2'-Deoxyuridine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: